DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia

Information source: Washington University School of Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Leukemia

Intervention: arsenic trioxide (Drug)

Phase: Phase 1/Phase 2

Status: Completed

Sponsored by: Washington University School of Medicine

Official(s) and/or principal investigator(s):
John F. DiPersio, MD, PhD, Principal Investigator, Affiliation: Washington University School of Medicine

Summary

The purpose of this study is to evaluate both the efficacy and toxicity of infusional arsenic trioxide in the treatment of patients with relapsed or refractory acute promyelocytic leukemia (APML). In addition, correlation between pharmacokinetic data and both therapeutic response and therapy-related toxicities will be sought.

Clinical Details

Official title: A Phase I/II Trial of Infusional Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment

Primary outcome:

Maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) or minimum effective dose (MED)

Efficacy (response and survival) at the MTD - Phase 2 only

Secondary outcome:

Acute and chronic toxicities

Evaluation of the pharmacokinetics and their correlation with toxicities and response

Evaluation of PML/RARA and PML protein redistribution and degradation following treatment and their correlation with response

Detailed description: OUTLINE: This is a dose-escalation study. Patients receive arsenic trioxide IV over 2 hours daily for 28 days followed by a 14 day rest period. Patients may receive up to 3 courses of treatment. Dose escalation continues in cohorts of 3-6 patients until the maximum tolerated dose (MTD) or minimum effective dose (MED) is determined. The MTD is defined as the dose preceding that at which 2 or more patients experience dose limiting toxicity. The MED is defined as the dose at which 4 of 6 patients achieve a complete cytogenetic or molecular response. After the MTD or MED is determined, an additional 20 patients are enrolled at this dose level. Patients are followed monthly for 6 months and every three months for an additional 1. 5 years.

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

INCLUSION CRITERIA 1. APML diagnosis based upon morphological, histochemical, and/or flow cytometric criteria, confirmed upon review by a central, study-designated hematologic pathologist; OR any relapsed acute leukemia bearing a t(15: 17) translocation or variant APML translocations involving the retinoic acid receptor alpha gene on chromosome 15q22, based on cytogenetics or PCR. 2. disease in first or subsequent relapse, following standard induction and consolidation chemotherapy (with all-trans retinoic acid) and/or allogeneic bone marrow/stem cell transplantation; OR failure to achieve initial complete remission with ATRA and standard chemotherapy. EXCLUSION CRITERIA 1. Availability of a fully HLA-matched sibling donor for patients otherwise felt to be candidates for allogeneic bone marrow/stem cell transplantation; patients with only a partially HLA-matched sibling or matched unrelated donor will remain eligible for study entry. 2. pregnancy. 3. Patients with significantly impaired left ventricular ejection fraction (<40%) will be ineligible for the study. Patients with renal failure and a creatinine clearance of less than 25 ml/min or requiring hemodialysis will be ineligible for the study. Otherwise, there are no rigid exclusion criteria based upon age, performance status, or co-morbidity. Decisions regarding enrollment of patients for whom these factors may be relevant will be individualized and left to the discretion of the investigators. Central venous access will be required for all patients. Patients of child-bearing potential must agree to use contraception during sexual intercourse while undergoing treatment with arsenic trioxide.

Locations and Contacts

Washington University School of Medicine, Saint Louis, Missouri 63110, United States
Additional Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Starting date: November 1998
Last updated: April 11, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017